Research Summary For patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM), prior reports have shown median progression-free survival (PFS) of less than six months and median overall survival (OS) of approximately one year. Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell...

Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is typically administered in the inpatient setting, but accessibility to outpatient administration is expanding. Benefits of outpatient CAR-T administration include broader treatment access, cost savings, reduced healthcare burden, and potentially improved patient quality of life. Ciltacabtagene autoleucel...

Research Summary Advances in T-cell redirecting therapy (TCRT), which includes chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engagers (TCEs), have favorably altered the treatment landscape of multiple myeloma (MM). Previous recommendations on TCRT use in relapsed/refractory MM (RRMM) were published by the International...

Research Summary Ciltacabtagene autoleucel (cilta-cel) is a second-generation autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA) on the surface of plasma cells. It is approved for patients with relapsed/refractory multiple myeloma (RRMM) with at least one prior line of therapy...

Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is an effective treatment option for relapsed/refractory multiple myeloma (RRMM). Nurses play a crucial role in the CAR-T therapy process, not only during, but also by providing patient care before and after administration. In this study, Steinbach...